EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nektar Therapeutics's enterprise value is $74.90 Mil.
Nektar Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-243.11 Mil. Therefore, Nektar Therapeutics's EV-to-EBITDA for today is -0.31.
The historical rank and industry rank for Nektar Therapeutics's EV-to-EBITDA or its related term are showing as below:
NKTR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1854.19 Med: -6.88 Max: 30.83
Current: -0.31
During the past 13 years, the highest EV-to-EBITDA of Nektar Therapeutics was 30.83. The lowest was -1854.19. And the median was -6.88.
NKTR's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs NKTR: -0.31
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Nektar Therapeutics's stock price is $1.38.
Nektar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.460. Therefore, Nektar Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nektar Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Nektar Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nektar Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Nektar Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's EV-to-EBITDA falls into.
Nektar Therapeutics EV-to-EBITDA Calculation
Nektar Therapeutics's EV-to-EBITDA for today is calculated as:
Nektar Therapeutics's current Enterprise Value is $74.90 Mil.
Nektar Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-243.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nektar Therapeutics's PE Ratio for today is calculated as:
Nektar Therapeutics's share price for today is $1.38.
Nektar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nektar Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your 